-
May 27, 2008
Gum disease may raise cancer risk, study finds
CHICAGO (Reuters) - Gum disease may increase the risk of developing cancer, researchers said on Tuesday.
-
April 21, 2008
Kidney cancer may be linked to multiple myeloma
NEW YORK (Reuters Health) - For the first time, researchers have evidence of an association between renal cell carcinoma and multiple myeloma, a type of blood cancer, one that "cannot be explained by random incidence alone," they say.
-
April 3, 2008
Thalidomide victims seek compensation, 50 years on
LONDON (Reuters) - Half a century after the launch of the notorious morning sickness pill thalidomide, its surviving victims are demanding 4 billion euros ($6.3 billion) in compensation from the German government and the drug's maker.
-
March 17, 2008
Overweight women have worse breast cancer: study
WASHINGTON (Reuters) - Breast cancer patients who are overweight have more aggressive disease and are likely to die sooner, U.S. researchers reported on Friday.
-
March 14, 2008
Locally advanced breast cancer more deadly in obese
WASHINGTON (Reuters) - Women with locally advanced breast cancer who are overweight have a worst prognosis than their slimmer counterparts, U.S. researchers reported on Friday.
-
February 15, 2008
British researchers link obesity to more cancers
LONDON (Reuters) - Obesity can double the risk of several cancers, according to a study published on Friday that for the first time also links being overweight with a number of less common forms of the disease.
-
February 11, 2008
"Jaws" actor Roy Scheider dead at 75
LOS ANGELES (Reuters) - Actor Roy Scheider, a two-time Oscar nominee best known for his roles as a small-town police chief in "Jaws" and his portrait of famed choreographer Bob Fosse in "All That Jazz," died on Sunday at age 75.
-
January 24, 2008
Marrow injections help kidney transplant success
BOSTON (Reuters) - Injecting blood or bone marrow cells into people who have just received a donated kidney can reduce the need for drugs that suppress the immune system, researchers reported on Wednesday.
-
December 10, 2007
Velcade boosts survival in multiple myeloma
BOSTON (Reuters) - Millennium Pharmaceuticals Inc said on Sunday that newly diagnosed patients with multiple myeloma who took its drug Velcade in combination with a standard regimen had significant improvement in overall survival, compared to patients who took the standard regimen alone.
-
December 10, 2007
Celgene's Revlimid delays myeloma progression
BOSTON (Reuters) - Celgene Corp said on Sunday that its cancer drug Revlimid in combination with the steroid dexamethasone helped newly diagnosed patients with multiple myeloma stave off their disease longer than those who took dexamethasone alone.
-
November 22, 2007
Drug boosts survival of relapsed multiple myeloma
NEW YORK (Reuters Health) - Adding the drug lenalidomide, a less-toxic relative of the drug thalidomide, to standard dexamethasone therapy can improve survival in patients with relapsed or hard-to-treat multiple myeloma -- a cancer of the blood.
-
October 5, 2007
Thalidomide improves myeloma survival in elderly
NEW YORK (Reuters Health) - Treatment with thalidomide, a drug made infamous decades ago for its link with severe birth defects, can improve the survival of elderly patients with multiple myeloma, a cancer affecting cells in the bone marrow, new research shows.
-
June 26, 2007
Bone drugs linked to jaw disease in cancer patients
NEW YORK (Reuters Health) - Corroborating previous evidence, the results of a large study strongly suggest that cancer patients treated with "bisphosphonates" are at increased risk for the destruction or "osteonecrosis" of the jawbone, according to a study in the Journal of the National Cancer Institute.
-
April 16, 2007
Experimental cancer drug may not affect heart
LOS ANGELES (Reuters) - Kosan Biosciences Inc. said new safety data from preclinical and early-stage clinical trials of tanespimycin show that the experimental cancer drug does not affect heart rhythms.
-
April 16, 2007
Amgen details higher death risk in Aranesp trial
LOS ANGELES (Reuters) - Amgen Inc. on Monday said 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared with 46 percent of patients on placebo as the company released details of a previously reported study.